中国实用儿科杂志

中国实用儿科杂志

• 论著 • 上一篇    下一篇

部分水解清蛋白配方粉预防过敏性疾病家族史阴性婴儿湿疹成本-效果关系初探

  

  1. 重庆医科大学附属儿童医院  儿童发育疾病研究教育部重点实验室  儿童发育重大疾病国家国际科技合作基地  儿科学重庆市重点实验室儿童保健科，重庆  400014
  • 出版日期:2016-04-06 发布日期:2016-04-12

Cost-effectiveness analysis of partially hydrolysed formula-whey on eczema prevention in infants without allergic family history

  1. Department of Primary Child Health Care，First Affiliated Hospital of Chongqing Medical University，Chongqing  400014，China
  • Online:2016-04-06 Published:2016-04-12

摘要：

目的    探讨部分水解清蛋白配方粉（pHF-W）预防过敏性疾病家族史阴性婴儿（非高危儿）湿疹发生的成本-效果关系。方法　以2013年6月至2014年4月重庆医科大学附属第一医院产科出生的50例足月新生儿作为研究对象， 通过问卷调查、 皮肤科就诊记录及电话回访记录等随访婴儿1岁内湿疹发生情况及诊治相关费用。比较两种不同喂养方式： pHF-W与普通标准配方粉（SF）喂养组预防非高危儿湿疹的成本-效果关系。其中婴儿湿疹由皮肤专科医生根据中国湿疹诊疗标准确诊。结果　至12个月时， 非高危儿湿疹总发生率为54.0%（27/50）； 采用pHF-W 喂养与 SF 喂养对非高危儿湿疹发生率差异无统计学意义（50.0% vs. 56.3%， P＞0.05）。与SF相比， 采用 pHF-W 喂养预防非高危儿湿疹不具有良好的成本-效果关系，成本-效果比 SF 喂养者高2003.2元/人。结论　采用pHF-W对预防非高危儿湿疹发生可能无疗效， 且在目前情况下不具有良好的成本-效果关系。

关键词: 过敏疾病家族史, 部分水解清蛋白配方粉, 婴儿湿疹, 成本-效果分析

Abstract:

Objective    To compare the incidence of eczema in infants without allergic family history and in those fed with partially hydrolysed formula-whey （pHF-W） or standard formula （SF），and to preliminarily discuss the preventive cost-effectiveness of those two formulas. Methods    Totally 50 healthy term newborns without allergic family history  born between June 2013 and April 2014 in Department of Obstetrics，the First Affiliated Hospital of Chongqing Medical University were enrolled. The incidence of infantile eczema and total cost for eczema were recorded during the 12 months of follow-up period.Cost-effectiveness of pHF-W vs. SF was compared according to the cost-effectiveness ratio. The infantile eczema was diagnosed by dermatologists according to Guidetines for Diagnosis and Treatment of Eczema in China. Results    The incidence of eczema in the infants was 54.0%（27/50） until 12 months old. There was no statistical significance of eczema incidence in the infants fed with pHF-W or SF（50.0% vs. 56.3%，P＞0.05）. Compared with SF，the good cost-effectiveness in pHF-W for eczema prevention did not exist in these infants，and the difference of cost-effectiveness ratio was ¥2003.2/person. Conclusion    There is no significant difference of eczema incidence in infants without allergic family history fed with pHF-W or SF in the first 4 months. egarding the cost-effectiveness，pHF-W is not superior to SF in eczema prevention.Hence，preventing infantile eczema by pHF-W seems not a wise choice in present medicare situation of China.

Key words: allergic family history, partially hydrolysed formula-whey, infantile eczema, cost-effectiveness analysis